JP2015530877A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530877A5
JP2015530877A5 JP2015525857A JP2015525857A JP2015530877A5 JP 2015530877 A5 JP2015530877 A5 JP 2015530877A5 JP 2015525857 A JP2015525857 A JP 2015525857A JP 2015525857 A JP2015525857 A JP 2015525857A JP 2015530877 A5 JP2015530877 A5 JP 2015530877A5
Authority
JP
Japan
Prior art keywords
human
response
gene
patient
adaptive immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015525857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530877A (ja
JP6559566B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/066425 external-priority patent/WO2014023706A1/en
Publication of JP2015530877A publication Critical patent/JP2015530877A/ja
Publication of JP2015530877A5 publication Critical patent/JP2015530877A5/ja
Application granted granted Critical
Publication of JP6559566B2 publication Critical patent/JP6559566B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015525857A 2012-08-06 2013-08-05 癌患者をスクリーニングするための方法及びキット Active JP6559566B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305975 2012-08-06
EP12305975.0 2012-08-06
PCT/EP2013/066425 WO2014023706A1 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019131862A Division JP6995091B2 (ja) 2012-08-06 2019-07-17 癌患者をスクリーニングするための方法及びキット

Publications (3)

Publication Number Publication Date
JP2015530877A JP2015530877A (ja) 2015-10-29
JP2015530877A5 true JP2015530877A5 (https=) 2016-09-23
JP6559566B2 JP6559566B2 (ja) 2019-08-14

Family

ID=46762994

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015525857A Active JP6559566B2 (ja) 2012-08-06 2013-08-05 癌患者をスクリーニングするための方法及びキット
JP2019131862A Active JP6995091B2 (ja) 2012-08-06 2019-07-17 癌患者をスクリーニングするための方法及びキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019131862A Active JP6995091B2 (ja) 2012-08-06 2019-07-17 癌患者をスクリーニングするための方法及びキット

Country Status (13)

Country Link
US (2) US20150218650A1 (https=)
EP (2) EP3470531A1 (https=)
JP (2) JP6559566B2 (https=)
AU (1) AU2013301609B2 (https=)
CA (1) CA2881389C (https=)
DK (1) DK2880180T3 (https=)
ES (1) ES2702722T3 (https=)
LT (1) LT2880180T (https=)
PL (1) PL2880180T3 (https=)
PT (1) PT2880180T (https=)
SG (1) SG11201500922RA (https=)
TR (1) TR201819211T4 (https=)
WO (1) WO2014023706A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
RU2020127099A (ru) * 2014-08-19 2020-09-02 Нэшнл Юниверсити Корпорейшн Окаяма Юниверсити Способ улучшения функции иммунных клеток и оценки мультифункциональности иммунных клеток
JP2018503373A (ja) * 2014-12-30 2018-02-08 ジェネンテック, インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
US20190309369A1 (en) * 2016-05-09 2019-10-10 Inserm (Institute National De La Sante Et De La Recherche Medicale) Methods for classifying patients with a solid cancer
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
US11311945B2 (en) 2018-03-22 2022-04-26 Sumitomo Electric Hardmetal Corp. Surface-coated cutting tool and method for manufacturing same
US20210381058A1 (en) * 2018-10-01 2021-12-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
CA3151629A1 (en) 2019-11-07 2021-05-14 Laura E. BENJAMIN Classification of tumor microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
JP7741831B2 (ja) 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び/又は死亡のリスクを予測するための方法
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
EP2157524A3 (en) * 2003-09-03 2010-12-08 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods for identifying, diagnosing, and predicting survival of lymphomas
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
CA2606018A1 (en) 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
DK2963011T3 (en) 2005-11-23 2018-08-06 Ventana Med Syst Inc MOLECULAR CONJUGATE
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
PT2619576T (pt) * 2010-09-24 2020-09-14 Niels Grabe Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION

Similar Documents

Publication Publication Date Title
JP2015530877A5 (https=)
WO2018007872A9 (en) Biomarkers for inflammatory bowel disease
JP2018505658A5 (https=)
Alegre et al. Circulating biomarkers in malignant melanoma
JP2014521308A5 (https=)
JP2015511721A5 (https=)
EP3744859A3 (en) Microrna biomarker for the diagnosis of gastric cancer
EP4417706A3 (en) Method for diagnosis and prognosis of chronic heart failure
JP2017525350A5 (https=)
CA2881389C (en) Methods and kits for screening patients with a cancer
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
JP2016500110A5 (https=)
JP2013066474A5 (https=)
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
JP2019176880A5 (https=)
JP2015064362A5 (https=)
JP2017503481A5 (https=)
JP2015210268A5 (https=)
WO2016130572A3 (en) Methods of determining levels of exposure to radiation and uses thereof
JP2013522589A5 (https=)
JP2020502498A5 (https=)
JP2013505008A5 (https=)
JP2018504909A5 (https=)
Lisboa et al. CCL8 and the immune control of cytomegalovirus in organ transplant recipients
Mourino-Alvarez et al. Proteomic characterization of EPCs and CECs “in vivo” from acute coronary syndrome patients and control subjects